CIRRH
MCID: LVR012
MIFTS: 62

Liver Cirrhosis (CIRRH)

Categories: Gastrointestinal diseases

Aliases & Classifications for Liver Cirrhosis

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 12 74 54 43 15 37 71
Cirrhosis 12 73 54 42 15 39 71
Cirrhosis of Liver 12 29 6 17
Cirrhosis, Cryptogenic 71
Cryptogenic Cirrhosis 73
Cirrh 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5082
MeSH 43 D008103
NCIt 49 C2951
SNOMED-CT 67 19943007
ICD10 32 K74.60
UMLS 71 C0023890 C0267809 C1623038

Summaries for Liver Cirrhosis

MedlinePlus : 42 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and primary biliary cirrhosis, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Liver Cirrhosis is FARSB (Phenylalanyl-TRNA Synthetase Subunit Beta), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and FOXA2 and FOXA3 transcription factor networks. The drugs Magnesium oxide and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood.

UniProtKB/Swiss-Prot : 73 Cirrhosis: A liver disease characterized by severe panlobular liver-cell swelling with Mallory body formation, prominent pericellular fibrosis, and marked deposits of copper. Clinical features include abdomen swelling, jaundice and pulmonary hypertension.

Wikipedia : 74 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, is a condition in which the liver does... more...

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1554)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 35.3 SLC17A5 HGF GPT F2 ALB AFP
2 primary biliary cirrhosis 33.8 SLC17A5 KRT18 IFNA1 GPT GGT1 F2
3 hepatic encephalopathy 33.6 SLC17A5 GPT F2 ALB AFP
4 alcohol use disorder 33.4 SLC17A5 HFE GPT GGT1 ALB
5 cholangitis, primary sclerosing 33.2 SERPINA1 GPT GGT1 F2 ALB AFP
6 cryptogenic cirrhosis 32.8 KRT8 KRT18 HFE F2
7 portal hypertension 32.7 GPT F2 ALB
8 hepatic coma 32.6 GPT F2 ALB AFP
9 hepatitis 32.6 SLC17A5 KRT8 KRT18 IFNA1 GPT GGT1
10 esophageal varix 32.4 SERPINA1 GPT GGT1 F2 ALB AFP
11 hepatorenal syndrome 32.2 REN GPT F2 ALB AFP
12 portal vein thrombosis 32.1 REN IFNA1 F2 AFP
13 hypersplenism 32.1 GPT F2 ALB
14 hepatitis b 32.1 SLC17A5 IFNA1 GPT GGT1 F2 ALB
15 cholelithiasis 31.8 SERPINA1 GPT GGT1 ALB
16 thrombocytopenia 31.8 IFNA1 GPT GGT1 F2 ALB
17 cholestasis 31.8 SLC17A5 SERPINA1 GPT GGT1 F2 ALB
18 acute kidney failure 31.8 REN HGF GPT F2 ALB
19 cholangitis 31.8 SLC17A5 GPT GGT1 F2 ALB
20 protein-energy malnutrition 31.8 GPT GGT1 ALB
21 schistosomiasis 31.6 GPT GGT1 F2 ALB
22 sclerosing cholangitis 31.6 GPT GGT1 F2 ALB
23 alpha-1-antitrypsin deficiency 31.6 SERPINA1 HFE GPT F2 ALB AFP
24 respiratory failure 31.6 SERPINA1 REN GPT F2 ALB
25 bilirubin metabolic disorder 31.5 SLC17A5 GPT GGT1 F2 ALB AFP
26 acute liver failure 31.5 SLC17A5 HGF GPT F2 ALB
27 obstructive jaundice 31.4 SLC17A5 REN HGF GPT GGT1 F2
28 glycogen storage disease 31.4 SLC17A5 HGF ALB AFP
29 acute cystitis 31.4 REN GPT F2 ALB
30 hepatitis d 31.4 IFNA1 GPT F2
31 wilson disease 31.4 HFE GPT F2 ALB
32 exanthem 31.4 IFNA1 GPT F2 ALB
33 siderosis 31.3 SERPINA1 HFE GPT
34 hypothyroidism 31.3 REN IFNA1 GPT F2 ALB
35 acute kidney tubular necrosis 31.3 REN HGF GGT1 ALB
36 tricuspid valve insufficiency 31.3 REN F2 ALB
37 choledocholithiasis 31.3 SLC17A5 GPT GGT1 F2 ALB
38 lipoprotein quantitative trait locus 31.3 REN GPT F2 ALB
39 hepatitis a 31.3 IFNA1 GPT GGT1 F2 ALB AFP
40 non-alcoholic steatohepatitis 31.3 KRT18 HGF HFE GPT GGT1 ALB
41 hepatitis e 31.3 GPT GGT1 F2 ALB
42 splenic infarction 31.3 GPT F2 ALB
43 infantile liver failure syndrome 1 31.2 SLC17A5 GPT F2 ALB
44 antipyrine metabolism 31.2 F2 ALB
45 fatty liver disease, nonalcoholic 1 31.2 SLC17A5 GPT GGT1
46 diarrhea 31.2 SERPINA1 REN IFNA1 GPT ALB
47 viral hepatitis 31.2 SLC17A5 SERPINA1 KRT8 KRT18 IFNA1 HGF
48 biliary atresia 31.2 HGF GPT GGT1 F2 ALB
49 pneumonia 31.2 SERPINA1 IFNA1 GPT F2 ALB
50 non-alcoholic fatty liver disease 31.1 KRT18 HFE GPT GGT1 ALB

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting, abdominal pain, constipation, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 730)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium oxide Approved Phase 4 1309-48-4 14792
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Insulin glulisine Approved Phase 4 207748-29-6
4
Nadolol Approved Phase 4 42200-33-9 39147
5
acetic acid Approved Phase 4 64-19-7 176
6
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
7
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 43805 6857599 5310940 9887054
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Prazosin Approved Phase 4 19216-56-9 4893
10
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
11
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
12
Temocillin Approved, Investigational Phase 4 66148-78-5
13
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
14
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
15
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
16
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
17
Thrombin Approved, Investigational Phase 4
18
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
19
Cefoxitin Approved Phase 4 35607-66-0 441199
20
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
21
Insulin lispro Approved Phase 4 133107-64-9
22
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
23
Dalteparin Approved Phase 4 9005-49-6
24
Pantoprazole Approved Phase 4 102625-70-7 4679
25
Colchicine Approved Phase 4 64-86-8 2833 6167
26
Simvastatin Approved Phase 4 79902-63-9 54454
27
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
28
Abatacept Approved Phase 4 332348-12-6 10237
29
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
30
Phylloquinone Approved, Investigational Phase 4 84-80-0
31
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
32
Zidovudine Approved Phase 4 30516-87-1 35370
33
Norepinephrine Approved Phase 4 51-41-2 439260
34
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
35
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
36
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
37
Losartan Approved Phase 4 114798-26-4 3961
38
Methylene blue Approved, Investigational Phase 4 61-73-4
39
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
40
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
41
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
42
Insulin aspart Approved Phase 4 116094-23-6 16132418
43
Insulin detemir Approved Phase 4 169148-63-4 5311023
44
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
45
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
46
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
47
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
48
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
49
Nicotine Approved Phase 4 54-11-5 942 89594
50
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444

Interventional clinical trials:

(show top 50) (show all 2712)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
2 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
3 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
4 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
5 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
6 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
7 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
8 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
9 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
10 A Prospective Randomized Controlled Trial of Efficacy and Safety of Anticoagulant Therapy With Low Molecular Weight Heparin and Warfarin in Portal Vein Thrombosis of Liver Cirrhosis Unknown status NCT04173429 Phase 4 Low molecular weight heparin (LMWH), warfarin
11 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
12 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
13 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
14 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
15 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
16 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
17 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
18 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
19 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
20 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
21 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
22 Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial Unknown status NCT02695732 Phase 4 Carvedilol
23 Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
24 The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
25 Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Unknown status NCT02074280 Phase 4 rifaximin
26 Rifaximin Reduces the Complications of Decompensated Cirrhosis Unknown status NCT02190357 Phase 4 Rifaximin
27 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
28 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
29 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
30 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
31 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
32 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
33 The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02638415 Phase 4 Carvedilol
34 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
35 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
36 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
37 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
38 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
39 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
40 Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues Unknown status NCT02982837 Phase 4 PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
41 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
42 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
43 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
44 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
45 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
46 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
47 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
48 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
49 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
50 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Bumetanide
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
Milk thistle extract
torsemide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 22121493 21771778
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived mesenchymal stem cells (family)
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Cirrhosis of Liver 29

Anatomical Context for Liver Cirrhosis

MalaCards organs/tissues related to Liver Cirrhosis:

40
Liver, Testes, Bone, Kidney, Spleen, Heart, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 47885)
# Title Authors PMID Year
1
Mutation of human keratin 18 in association with cryptogenic cirrhosis. 6 54 61
9011570 1997
2
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. 54 6
12724528 2003
3
Keratin 8 mutations in patients with cryptogenic liver disease. 54 6
11372009 2001
4
Acute Liver Injury and Decompensated Cirrhosis. 42 61
32505258 2020
5
The effect of vitamin D supplementation on the progression of fibrosis in patients with chronic liver disease: A protocol for a systematic review and meta-analysis. 42
32384521 2020
6
Gastroduodenal Surgery in Cirrhotic Patients - Case Series and Literature Review. 42
32369726 2020
7
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 61 54
20189618 2010
8
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 61 54
20428787 2010
9
Hemodynamic effects of chronic smoking in liver cirrhosis: a role for adrenomedullin. 54 61
20216319 2010
10
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 54 61
19582578 2010
11
Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. 61 54
19920809 2010
12
Splanchnic concentrations and postprandial release of visceral adipokines. 61 54
19913846 2010
13
Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. 61 54
19495975 2010
14
Hepatic osteodystrophy and liver cirrhosis. 54 61
20355242 2010
15
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. 54 61
20357999 2010
16
Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. 54 61
20346216 2010
17
Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. 61 54
20350877 2010
18
Alpha-fetoprotein gene polymorphisms and risk of HCC and cirrhosis. 54 61
19968979 2010
19
Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. 54 61
19406586 2010
20
Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. 54 61
19593164 2010
21
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 54 61
19877168 2010
22
Increased bactericidal/permeability increasing protein in patients with cirrhosis. 61 54
19765220 2010
23
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 54 61
19864937 2010
24
[Relationship between quality of life and basic syndromes of traditional Chinese medicine in patients with posthepatitic cirrhosis]. 61 54
20082755 2010
25
Hepatitis B virus load in serum does not reflect histologic activity in patients with decompensated cirrhosis. 54 61
19804841 2010
26
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. 61 54
19793171 2010
27
Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. 54 61
20118733 2010
28
[Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues]. 54 61
20128976 2010
29
Severe sepsis in cirrhosis. 61 54
19885876 2009
30
[Monitoring patients with chronic hepatitis during and after therapy]. 61 54
20198895 2009
31
Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. 54 61
20214224 2009
32
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 54 61
19917415 2009
33
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. 54 61
19797428 2009
34
A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. 54 61
19676133 2009
35
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. 54 61
19243500 2009
36
Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis. 61 54
19619258 2009
37
Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. 61 54
19608867 2009
38
Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. 61 54
19642174 2009
39
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 61 54
19719920 2009
40
Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. 61 54
19294419 2009
41
Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. 54 61
19760951 2009
42
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 61 54
19413694 2009
43
[Comparison of the serum proteomes of pathological stages during hepatocarcinogenesis]. 61 54
19912687 2009
44
Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. 54 61
19365625 2009
45
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. 61 54
19201777 2009
46
Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. 54 61
19478697 2009
47
Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. 61 54
19552764 2009
48
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 61 54
19207581 2009
49
Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. 54 61
19264859 2009
50
Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. 61 54
19212316 2009

Variations for Liver Cirrhosis

ClinVar genetic disease variations for Liver Cirrhosis:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FARSB NM_005687.5(FARSB):c.1381A>C (p.Thr461Pro)SNV Pathogenic 545642 rs1396171148 2:223478611-223478611 2:222613892-222613892
2 FARSB NM_005687.5(FARSB):c.784A>G (p.Lys262Glu)SNV Pathogenic 545655 rs1553554543 2:223496325-223496325 2:222631606-222631606
3 FARSB NM_005687.5(FARSB):c.1202G>A (p.Arg401Gln)SNV Pathogenic 545664 rs1553553086 2:223488418-223488418 2:222623699-222623699
4 FARSB NM_005687.5(FARSB):c.755T>C (p.Phe252Ser)SNV Pathogenic 545694 rs1466642025 2:223496354-223496354 2:222631635-222631635
5 FARSB NM_005687.5(FARSB):c.226T>C (p.Cys76Arg)SNV Pathogenic 545695 rs1419129874 2:223507613-223507613 2:222642894-222642894
6 KRT18 NM_000224.3(KRT18):c.383A>T (p.His128Leu)SNV Pathogenic,risk factor 14585 rs57758506 12:53343340-53343340 12:52949556-52949556
7 KRT8 NM_002273.4(KRT8):c.184G>T (p.Gly62Cys)SNV Pathogenic,risk factor 14630 rs11554495 12:53298582-53298582 12:52904798-52904798
8 KRT8 NM_002273.4(KRT8):c.160T>C (p.Tyr54His)SNV Uncertain significance 14631 rs57749775 12:53298606-53298606 12:52904822-52904822

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.05 SERPINA1 HGF ALB AFP
2 10.78 F2 ALB AFP
3 10.23 MEG3 HOTAIR

GO Terms for Liver Cirrhosis

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.46 SERPINA1 F2 ALB AFP
2 extracellular space GO:0005615 9.32 SERPINA1 REN IFNA1 HGF HFE GPT
3 platelet alpha granule lumen GO:0031093 9.13 SERPINA1 HGF ALB

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.26 SERPINA1 F2 ALB AFP
2 hepatocyte apoptotic process GO:0097284 9.16 KRT8 KRT18
3 acute-phase response GO:0006953 8.8 SERPINA1 HFE F2

Sources for Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....